Abstract
Combination of chemotherapeutic agents and angiogenesis inhibitors is now commonly employed in the clinic to treat cancer. Here, we used angiostatic agents anginex and 0118, in combination with the chemotherapeutic irofulven, to treat human ovarian tumor xenografts in mice. General linear mixed models were used to statistically analyze tumor growth curves. Overall, combination of a low, non-toxic dose of irofulven with either angiogenesis inhibitor was more effective at inhibiting tumor growth than any of the single agent therapies. For example, the anginex/irofulven and 0118/irofulven combinations inhibited tumor growth relative to controls by 92% (p < 0.0001) and 96% (p < 0.0001), respectively, with the 0118/irofulven combinations yielding 100% complete responses. This study suggests that combination therapy of 0118 or anginex and irofulven may be highly effective in the clinical setting.
Original language | English (US) |
---|---|
Pages (from-to) | 270-280 |
Number of pages | 11 |
Journal | Cancer Letters |
Volume | 265 |
Issue number | 2 |
DOIs | |
State | Published - Jul 8 2008 |
Bibliographical note
Funding Information:This research was supported by research grants to K.H.M. from the National Cancer Institute (NIH CA-096090) and from MGI Pharma, Inc., Bloomington, MN, and to R.J.G. from the National Cancer Institute (NIH CA-107160).
Keywords
- Anginex
- Angiogenesis
- Chemotherapy
- Galectin-1
- Irofulven